Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma

por De Divitiis, C., von Arx, C., Grimaldi, A. M., Cicala, D., Tatangelo, F., Arcella, A., Romano, G. M., Simeone, E., Iaffaioli, R. V., Ascierto, P. A., Tafuto, S.
Publicado 2016